This is a working overview of SR9009, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-09-12 and is reviewed periodically as new material appears.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.
Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic small molecule | Studied as a REV-ERB agonist |
| Molecular formula | C20H24ClN3O4S | Reported for the neutral compound |
| Appearance | Off-white to pale yellow solid | Typical research-grade material |
| Solubility | Sparingly soluble in water | Soluble in solvents such as DMSO |
| Common synonyms | SR9009; Stenabolic | Stenabolic is an informal alias |
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
Michael desired to restore the empire's glory through a rebuilding programme in Constantinople, clever diplomatic alliances, and expansionist wars in Europe. He staved off the threatening Charles I of Anjou first by recognising papal primacy and certain Catholic doctrines at the 1274 Second Council of Lyon, and then by aiding the Sicilian Vespers against Charles in 1282. However, his religious concessions were despised by most of the populace, and were repudiated by his successor Andronikos II (r. 1282–1328). He and his grandson Andronikos III (r. 1328–1341) led several campaigns to restore imperial influence, succeeding in Epirus and Thessaly. Their policies also weakened the state, including the dismissal of the fleet in 1285, the hiring of the mercenary Catalan Company, which turned on the Byzantines in the 1300s, and their civil war between 1320 and 1328. A disastrous civil war between 1341 and 1354 caused long-term economic difficulties, while the Ottoman Turks gradually expanded.
Thy-1 or CD90 (Cluster of Differentiation 90) is a 25–37 kDa heavily N-glycosylated, glycophosphatidylinositol (GPI) anchored conserved cell surface protein with a single V-like immunoglobulin domain, originally discovered as a thymocyte antigen. Thy-1 can be used as a marker for a variety of stem cells and for the axonal processes of mature neurons. Structural study of Thy-1 led to the foundation of the Immunoglobulin superfamily, of which it is the smallest member, and led to some of the initial biochemical description and characterization of a vertebrate GPI anchor and also the first demonstration of tissue specific differential glycosylation.
=== Sexual adverse effects === Use of finasteride is associated with an increased risk of sexual dysfunction including erectile dysfunction, decreased libido and ejaculatory dysfunction. Sexual adverse effects of finasteride and dutasteride have been linked to lower quality of life and ability to maintain an intimate relationship, and can cause stress in relationships. The adverse effect profiles of finasteride are somewhat different for its indications of hair loss and BPH.
Sources: en.wikipedia.org
The jury acquitted Letby of the attempted murder on counts 9 (Baby G) and 10 (Baby H), and was unable to reach verdicts on counts 11 (Baby H), 13 (Baby J), 14, (Baby K), 18 and 19 (Baby N), and 22 (Baby Q). On 21 August 2023, Letby was sentenced to life imprisonment with a whole life order, the most severe penalty available under English law. She became the fourth woman in the UK to receive such a sentence. In his remarks, Goss described her actions as "a cruel, calculated and cynical campaign of child murder involving the smallest and most vulnerable of children", adding that "there was a deep malevolence bordering on sadism [...] you [Letby] have no remorse [...] there are no mitigating factors [...] the offences are of sufficient severity to require a whole life order." Letby chose not to attend the sentencing hearing and therefore did not hear the victim impact statements or the sentence being passed. In response, the Secretary of State for Justice, Alex Chalk, said the government would "look at options to change the law at the earliest opportunity" to require defendants to attend their sentencing. Following the trial, Letby was transferred to HMP Low Newton in County Durham. As of February 2025, she is held at HM Prison Bronzefield.
=== Side effects === The most common side effects during treatment with vasopressin are dizziness, angina, chest pain, abdominal cramps, heartburn, nausea, vomiting, trembling, fever, water intoxication, pounding sensation in the head, diarrhoea, sweating, paleness, and flatulence. The most severe adverse reactions are myocardial infarction and hypersensitivity.
This activation of the renin-angiotensin axis further prompts increased biosynthesis of aldosterone; whereas plasma and urinary aldosterone levels are increased early in the course of treatment with minoxidil, over time these values tend to normalize presumably because of accelerated metabolic clearance of aldosterone in association with hepatic vasodilation. Minoxidil may be involved in the inhibition of serotonin 5-HT2 receptors. Minoxidil might increase blood–tumor barrier permeability in a time-dependent manner by downregulating tight junction protein expression and this effect could be related to ROS/RhoA/PI3K/PKB signal pathway. Minoxidil significantly increases ROS concentration when compared to untreated cells. Minoxidil treatment resulted in a "0.22-fold change" for 5α-reductase 2 (p < 0.0001) in vitro. This antiandrogenic effect of minoxidil, shown by significant downregulation of 5α-reductase 2 gene expression in HaCaT cells, may be one of its mechanisms of action in alopecia. The effects of minoxidil have been found to mimic the symptoms of Cantú syndrome, which involves gain-of-function mutations in KATP channel subunits (specifically SUR2 and KIR6.1). Examples of these minoxidil effects are hypertrichosis, pericardial effusions, pulmonary hypertension, edema, and coarsening of facial features. Relatedly, there has been concern that excessive doses of minoxidil and other KATP potassium channel openers might cause a "drug-induced Cantú syndrome".
Sources: en.wikipedia.org
== Description == Eucalyptus globulus is a tree that typically grows to a height of 45 m (148 ft) but may sometimes only be a stunted shrub, or alternatively under ideal conditions can grow as tall as 90 m (300 ft), and forms a lignotuber. The bark is usually smooth, white to cream-coloured but there are sometimes slabs of persistent, unshed bark at the base. Young plants, often several metres tall, and coppice regrowth have stems that are more or less square in cross-section with a prominent wing on each corner. Juvenile leaves are mostly arranged in opposite pairs, sessile, glaucous elliptic to egg-shaped, up to 150 mm (5.9 in) long and 105 mm (4.1 in) wide. Adult leaves are arranged alternately, the same glossy to dark green on both sides, lance-shaped or curved, 150–300 mm (5.9–11.8 in) long and 17–30 mm (0.67–1.18 in) wide on a petiole 1.5–6 mm (0.059–0.236 in) long. The flower buds are arranged singly or in groups of three or seven in leaf axils, sometimes sessile or on a short thick peduncle. The individual buds are also usually sessile, sometimes on a pedicel up to 5 mm (0.20 in) long. Mature buds are top-shaped to conical, glaucous or green, with a flattened hemispherical, warty operculum with a central knob. Flowering time varies with subspecies and distribution but the flowers are always white. The fruit is a woody conical or hemispherical capsule 2–3 cm diameter with the valves close to rim level.
Anorexia nervosa (AN), commonly referred to as anorexia, is an eating disorder characterized by predominant food restriction, body image disturbance, fear of gaining weight, and an overwhelming desire to be thin. These characteristics often mean individuals undergo severe malnutrition as a result of the disorder. Individuals with anorexia nervosa have a fear of gaining weight, despite the fact that they are typically underweight. The DSM-5 describes this perceptual symptom as "disturbance in the way in which one's body weight or shape is experienced". Recent research has shown that this disturbance is based not on visual body-size overestimation but rather on body dissatisfaction: individuals with anorexia can accurately visually identify their body size, but find severely underweight bodies the most attractive. Individuals with anorexia nervosa may also deny that their symptoms or behaviors are indicative of illness. They may weigh themselves frequently, eat small amounts, and only eat certain foods in order to be in as much control of their body appearance as possible. Some patients with anorexia nervosa binge eat and purge to further influence their weight or shape. Purging can manifest as induced vomiting, excessive exercise, and/or laxative abuse. Anorexia nervosa has the highest mortality rate of any psychiatric diagnosis. Medical complications may include osteoporosis, infertility, and heart damage, along with the cessation of menstrual periods and death. Complications in males may include lowered testosterone.
Three TTP militants were killed while attacking a border post in Panjgur District. A suicide VBIED attack on a police post in Dera Ghazi Khan District killed two personnel and wounded three others. An abandoned police post was blown up by militants in Khyber District. On 15 June, Ali Malang group from Nowshera and Khattab group in Makran Division formally pledged allegiance to TTP. A civilian was killed while six soldiers and three labourers were injured in a TTP drone strike targeting the construction site of a Pakistani military post in Spinwam. An On alleged militant and a facilitator were captured during an infiltration attempt from Tirah valley into Orakzai District. On 16 June, a Pakistan Army post was hit by a drone strike and insurgents blew up a gas pipeline in Lakki Marwat District, a CCTV camera was also targeted with an IED. In Khyber District, two engagements took place between Peace Committee members and militants, one near the house of a peace committee member where five were killed and the other when insurgents were evacuating their wounded. Three bodies including a dead TTP commander were recovered from Bannu District. FC Balochistan conducted an operation in Chagai District capturing weapons and ammunition originating from Afghanistan. An IMP insurgent was killed in a military operation in North Waziristan. Three TTP insurgents were killed in a military operation in Kohat District and three more in Charsada District. In South Waziristan, two FC soldiers were killed in an engagement with militants.
Among Catholics, the positive rating decreased from 48% to 24%, and among evangelicals, from 30% to 21%. In the Northeast, traditionally a region of greater support for the president, approval fell from 49% to 33%. The survey was carried out between 10 and 11 February, with 2,007 voters from 113 cities, and has a margin of error of two percentage points. On 29 May, the study "Vida Digital de Lula", launched by the Ativaweb agency, identified that Lula lost one million followers on the social networks Instagram and Facebook. According to the study, the reasons would be the triggering of the INSS fraud scheme initiated in 2019 and the taxation of the Tax on Financial Operations (IOF). According to the portal O Antagonista, one of the reasons would be the embarrassments caused by first lady Janja. The AtlasIntel survey carried out on 30 May showed that disapproval rates of Lula's government reached the record level of 53.7%, according to the survey conducted in partnership with Bloomberg. This is the highest rate of dissatisfaction with the current administration since January 2024, due to the start of the investigations into the INSS fraud scheme. Approval of the PT government remained stable at 45.5% – in April, it was 46.1%, and in March, 44.9%. The Quaest survey released on 16 July indicated a recovery in the rating, according to the survey, because the difference between approval and disapproval was 17 points in June and 10 now. Disapproval, however, remained above approval, with 53% disapproval and 43% approval.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.
No. SR9009 is frequently mislabeled as a SARM in online discussions, but it does not target androgen receptors. Its known mechanism involves REV-ERB nuclear receptors and circadian-metabolic gene regulation.
Human clinical data are very limited. There is no approved human use, and safety and efficacy in people are not established. Most evidence comes from preclinical models, so effects observed in animals may not apply to humans.
Liquid chromatography-tandem mass spectrometry is a common approach. It can detect the parent compound and its metabolites in biological matrices.